Stock Events

Stock Events

Evotec 

€1.4700
386
+€0.00+0%Friday 15:04

Statistics

Day High
1.47
Day Low
1.39
52W High
3.38
52W Low
1.02
Volume
-
Avg. Volume
-
Mkt Cap
522.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-0.8
-0.24
0.31
0.87
Expected EPS
-0.3568446
Actual EPS
-0.3568446

Financials

-13.13%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
788.37MRevenue
-103.52MNet Income

Analyst Ratings

$3.79Average Price Target
The highest estimate is ⁦3.79⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVTA.F. It's not an investment recommendation.
Basf
29
BAS.XETRA
Bayer
29
BAYN.XETRA
Microsoft
25
MSFT
NVIDIA
24
NVD.XETRA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Evotec's drug discovery platforms, making them direct competitors in the biotech innovation space.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on creating new treatments for serious diseases, directly competing with Evotec's drug discovery and development services.
Novartis
NVS
Mkt Cap303.67B
Novartis is a large pharmaceutical company that competes with Evotec in the drug discovery and development sector, particularly in the development of novel therapeutics.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that competes with Evotec in the area of drug discovery, development, and commercialization, especially in the fields of antiviral drugs.
AMGEN
AMGN
Mkt Cap251.94B
Amgen is a biotechnology firm focusing on human therapeutics, competing with Evotec in drug discovery and development, particularly in the biotech sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, competing with Evotec in drug discovery and development, especially in the area of monoclonal antibodies.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases, competing with Evotec in the niche market of rare diseases drug discovery.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with Evotec in the development of novel RNA-based therapies.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics competes with Evotec in the cutting-edge field of gene editing, specifically using base editing technology to develop precision genetic medicines.

About

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Show More
CEO
Christian Wojczewski
Employees
4553
Country
Germany
ISIN
US30050E1055
WKN
000A0QZ3J

Listings

STU
DE
EVT.STU
STU
DE
EVTA.STU
MU
DE
EVT.MU
MU
DE
EVTA.MU

0 Comments

Share your thoughts

FAQs

What is Evotec stock price today?▼
The current price of EVTA.F is €1.47 EUR — it has increased by +0% in the past 24 hours. Watch Evotec stock price performance more closely on the chart.
What is Evotec stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Evotec stocks are traded under the ticker EVTA.F.
Is Evotec stock price growing?▼
EVTA.F stock has risen by +13.08% compared to the previous week, the month change is a +5% rise, over the last year Evotec has showed a -46.35% decrease.
What is Evotec market cap?▼
Today Evotec has the market capitalization of 522.42M
When is the next Evotec earnings date?▼
Evotec is going to release the next earnings report on April 14, 2027.
What were Evotec earnings last quarter?▼
EVTA.F earnings for the last quarter are -0.32 EUR per share, whereas the estimation was -0.32 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Evotec revenue for the last year?▼
Evotec revenue for the last year amounts to 788.37M EUR.
What is Evotec net income for the last year?▼
EVTA.F net income for the last year is -103.52M EUR.
How many employees does Evotec have?▼
As of November 7, 2026, the company has 4,553 employees.
In which sector is Evotec located?▼
Evotec operates in the Health & Wellness sector.
When did Evotec complete a stock split?▼
The last stock split for Evotec was on October 20, 2021 with a ratio of 4:1.
Where is Evotec headquartered?▼
Evotec is headquartered in Hamburg, Germany.